We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Provexis Plc | LSE:PXS | London | Ordinary Share | GB00B0923P27 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.65 | 0.60 | 0.70 | - | 1,153 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Food Preparations, Nec | 390k | -385k | -0.0002 | -32.50 | 14.42M |
Date | Subject | Author | Discuss |
---|---|---|---|
23/12/2015 14:46 | sleveen That's not clear yet, a trial should shortly be under way to get a first stab at an answer. If that replicates the trial Duttaroy ( who's now working for Provexis ) did with hypertensive patients by seeing the effect of adding kiwi fruits to their daily diet ( ) that showed a reduction in 10 systolic and 9 diastolic in hypertensives. But that trial was just for middle aged to elderly male smokers. The company are currently saying, about the first lab trail, "... provided strong evidence that a standard dose of Fruitflow® has the potential to give a clinically relevant reduction in systolic blood pressure". What's "clinically relevant" you might ask ? I don't know the answer to that. BB | bareknee | |
23/12/2015 13:48 | BB, yes, I bought some this week, will maybe buy a few more if it dips further but not a massive stake. Got a couple of bad'uns this year, ALPH and AAL, but have had a few very good years so will put this down as a blip. Short on BLT softened the drop in AAL but still not nice :-( All the best for XMAS and 2016. | senor_sensible | |
23/12/2015 13:24 | By how many mmHg does this miracle food actually lower bp? Systolic and diastolic please. | sleveen | |
23/12/2015 12:24 | I wouldn't be so sure about that SS. The Fruitflow / Resveratrol trial results are likely to be out before any funding is required, but the Stage 1 BP trials are pretty much repeating what Duttaroy's already done and the Stage 2 trials havn't started yet. As an aside, how weird is it that, as far as I can remember, Provexis has never mentioned the memory trails. Maybe they meant to but just forgot ? I don't think the share price will fall off a cliff, but it's quite likely to continue drifting down until either the market makers have a play with it or something pretty significant happens. Good luck if you're buying at the moment, you're certainly a getting the shares a damned sight cheaper than I got mine for ! Merry Christmas to one and all. Barring Provexis, and one other pup, it's been another decent year for me on the markets. Hopefully you've all done OK this year and will do even better in 2016 ! | bareknee | |
23/12/2015 09:44 | Much to the surprise of some the price has remained fairly stable, this might be the cheapest price you can get for this, any future capital raising will most likely be done at a premium to the current share price IMO. Reservatol trial and BP trial both will have an update prior to any new capital raising, plus there is the IP on plantains too which seems to be coming back to life so some good news flow first. Next capital raising might not be open to outsiders :-) Merry XMAS | senor_sensible | |
22/12/2015 16:35 | Here's where I admit I don't know really, but it seems to me that there's more to the BP trials than most realise. Off the top of my head; - most potential drug candidates fail because of toxicity, dose related problems and the like. Although we're at early phase 1 (maybe 2?) trials we know, almost certainly, that there are no side effects. In effect, once a small cheap trial is done as proof of concept, this 'drug' is essentially ready for JV pharma work quite quickly. - with a bit of tweaking, which is likely, the result should not interfere with our FF market. To my mind this seems realistic. - a pharmaceutical firm might be interested in our patents to do with bioactivity etc. as opposed to patents to do with manufacture of FF. I guess we could cover both via different funding agreements but I'm not sure. From a scientific perspective, we might have access rights to a parent molecule giving multiple resultant drug candidates. Fantasy? Perhaps but with some justification. I'm pleased that we're finally doing something interesting and I'll be more than happy to support further funding in the interim to get us to JV stage talks. ps. You're not boring really, Happy Christmas. :) | librag | |
22/12/2015 15:00 | hxxp://journals.plos the University of Liverpool and Provexis plc, holds a patent for use of a soluble fibre preparation as maintenance therapy for Crohn's disease | senor_sensible | |
22/12/2015 13:09 | lol, I thought it was a ~5k buy when it went through this am. See the big spenders are about again. Just off to specsavers. | senor_sensible | |
22/12/2015 11:32 | SS Is this it ? :- From ISDX 8:04 134,585 @ 0.35 Less than £500 ? BB | bareknee | |
22/12/2015 10:34 | Think we will see a tick up later, some 0.35p buys still not showing :-) | senor_sensible | |
22/12/2015 09:09 | Now is a much better time to buy than any time in the past 9 years | senor_sensible | |
22/12/2015 08:50 | They are going to do some more fund raising how is this a good time to buy ss? | balbains324 | |
22/12/2015 08:15 | lol, no comment from the LTH Pixies, must be a shock to see improvement in situation after they predicted it for the last 9 years. now is the time to start building the investment :-) | senor_sensible | |
22/12/2015 07:57 | StockMarketWire.com Provexis has widened its H1 pretax loss to GBP228,447, from a loss of GBP207,542. Revenue was GBP40,908, from GBP8261. "The first six months of the year have seen a number of very positive developments for the business, and with the Company's low operational costs we are well positioned to drive value for shareholders," said executive chairman Dawson Buck. "We remain positive about the outlook for the business for the second half of the year and beyond." | senor_sensible | |
22/12/2015 07:40 | Reading between the lines looks like some good growth in revenue plus starting to turn on the R&D with some IBD, fruitflow, BP work. Confident enough to increase their R&D spend. Could be enough to raise spirits.... | senor_sensible | |
18/12/2015 12:18 | Ah, I see. For me, I stopped using stochastics a long time ago. TBH I didn't know the Williams%R was an inverse of it, so we live and learn. I don't read oversold in MACD (flat or dropping) or RSI (possibly divergent but very short term) so overall I'm not sure I agree with you. There you go, the kiss of death. share price will rocket now. :) | librag | |
18/12/2015 11:37 | Indicates oversold :-) Not the strongest signal but it is what it is...... | senor_sensible | |
18/12/2015 09:23 | Short term bullish signal today, let's see what this develops into | senor_sensible | |
17/12/2015 12:37 | arghhhhh, Libra has the power to post Phalic pictures..... | senor_sensible | |
17/12/2015 12:31 | This has to be the future. | librag |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions